|
⚲
|
| Keyboard |
| Sectoral Asset Management Inc
✚
|
|
|---|---|
| CRD # | 110345 |
| SEC # | 801-60079 |
| CIK # | 0001274413 |
| AUM | 331.4 M (2026-05-06) |
| Employees | 20 (55% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 514-849-8777 |
| Address | 1010 Sherbrooke Street, West Montreal Quebec, Canada |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/26/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation Separate Accounts - Basic Fee Schedule: The Adviser charges a fee consisting of a percentage of assets under management. The Adviser’s basic fee schedule is equal, on an annual basis, to 1% of assets under management. The basic fee schedule is negotiable. In certain circumstances, the Adviser may negotiate a performance fee arrangement, which will comply with the applicable requirements of Rule 205-3 under the Investment Advisers Act of 1940 (the “Advisers Act”). Fees are payable in arrears, on a monthly, quarterly, or semi-annual basis, based on the average market value of assets under management for the given period. Compensation is not payable before the services are provided. Investors will normally incur fees related to custody and administration services, which will be also disclosed in relevant prospectus. Additionally, investors will normally incur brokerage and other transaction costs (refer to section 12). Public Investment Funds: The fee schedule is defined in the prospectus of each fund. The management fee may vary for each share class as determined in the pertinent prospectus. Investors will normally incur fees related to custody and administration services, which will be also disclosed in relevant prospectus. Additionally, investors will normally incur brokerage and other transaction costs (refer to section 12). Venture Capital Funds: The Adviser acts as investment adviser to the venture capital funds that are exempt from registration under the Investment Company Act. The management fee structure is defined in the governing document of each fund, the Limited Partnership Agreement (“LPA”). For the New Emerging Medical Opportunities (“NEMO”) venture capital funds, the Adviser receives management fee for the advisory services provided equal to, on a quarterly basis, 0.5% (2.0% on an annual basis) of the aggregate committed capital during the investment term, as defined in the LPA. After the expiration of the investment term, the fee is equal to, on a quarterly basis, 0.3125% (1.25% on an annual basis) of the aggregate committed capital until the end of the fund’s life. For Medtech Ventures Fund, the Adviser receives management fee for the advisory services provided equal to, on a quarterly basis, 0.625% (2.5% on an annual basis) of the aggregate committed capital, plus any applicable sales tax, during the investment term, as defined in the LPA. After the expiration of the investment term, the fee is equal to, on a quarterly basis, 0.5% (2.0% on an annual basis) of the net invested capital plus any applicable sales tax, as defined in the LPA, until the end of the fund’s life. The Adviser may enter into agreements that have the economic effect of waiving, in whole or in part, the management fee borne by any Limited Partner. In addition, the venture capital funds charge carried interest as defined in each fund’s governing document. The Adviser is allocated a portion of the carried interest charged to the Fund; the allocation percentage is determined at the discretion of the General Partner of each fund. The management and performance-based fees charged to each of the venture capital fund are in addition to the other fees and expenses borne by such funds, including, but not limited to, organizational expenses, investment expenses (i.e., expenses related to the investment of the fund’s assets, including, without limitation, brokerage commissions and interest expense), legal expenses, audit and tax preparation expenses, taxes, fees and expenses of third-party administrators, directors, depository banks, custodians, and other service providers, expenses relating to the transfer of interests, and all other extraordinary expenses. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/26/2026) [Brochure] |
|---|
Item 7 – Types of Clients Sectoral provides portfolio management services to investment companies (including mutual funds) and venture capital funds. Certain funds managed by Sectoral may not be available to U.S. investors, may limit the number of U.S. investors they will accept, or may require that any U.S. investors certify that they are “qualified purchasers” as defined in Section 2(a) (51) of the Investment Company Act of 1940. These funds also may impose qualification requirements with respect to non-U.S. investors. Investors in venture capital funds managed by Sectoral generally are required to meet certain conditions, including a minimum initial investment (typically $1 million), minimum subsequent investments (typically $100,000), and other qualifications, such as net worth, investment sophistication, and country of residence. The funds may waive the minimum investment requirements at their discretion. Investors must submit a complete subscription agreement. Shares in certain funds managed by Sectoral may not be available to investors in certain markets. In addition, certain of the funds managed by Sectoral limit the ability of investors to withdraw capital or redeem or transfer their shares for a period of time after investment. These withdrawals, redemption or transfer provisions may differ among the different funds managed by Sectoral. A fund may waive or alter these requirements. |
| CIK | Period |
|---|---|
| 0001274413 |
| Sector | Form 13F Holdings | Value ($B) |
|---|---|---|
| Evommune Inc | 0.0 | |
| Contineum Therapeutics Inc | 0.0 | |
| Shoulder Innovations Inc | 0.0 | |
| Lilly Eli & Co | 0.0 | |
| Johnson & Johnson | 0.0 | |
| Gilead Sciences Inc | 0.0 | |
| UnitedHealth Group Inc | 0.0 | |
| Amgen Inc | 0.0 | |
| Vertex Pharmaceuticals Inc / Ma | 0.0 | |
| Insmed Inc | 0.0 | |
| Argenx SE | 0.0 | |
| AbbVie Inc | 0.0 | |
| Abbott Laboratories | 0.0 | |
| Merck & Co Inc | 0.0 | |
| Regeneron Pharmaceuticals Inc | 0.0 | |
| Intuitive Surgical Inc | 0.0 | |
| Boston Scientific Corp | 0.0 | |
| Biontech SE | 0.0 | |
| Stryker Corp | 0.0 | |
| Danaher Corp /DE/ | 0.0 | |
| Thermo Fisher Scientific Inc | 0.0 | |
| Dexcom Inc | 0.0 | |
| Quintiles Transnational Holdings Inc | 0.0 | |
| Summit Therapeutics PLC | 0.0 | |
| Edwards Lifesciences Corp | 0.0 | |
| Bristol Myers Squibb Co | 0.0 | |
| United Therapeutics Corp | 0.0 | |
| Vera Therapeutics Inc | 0.0 | |
| Arcus Biosciences Inc | 0.0 | |
| Roivant Sciences Ltd | 0.0 | Prev | Page 1 | Next |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | New Emerging Medical Opportunities Fund VI SCSP | 2026-03-26 | 40.6 M | |
| PE | New Emerging Medical Opportunities Fund V SCSP | 2022-03-31 | 97.4 M | |
| PE | New Emerging Medical Opportunities Fund IV SCSP | 2019-03-29 | 72.4 M | |
| PE | New Emerging Medical Opportunities Fund III LP | 2016-03-29 | 2.2 M | |
| Other | Sectoral Emerging Markets Healthcare Fund LP | [2016-03-29] | ||
| Filed 2018-08-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | New Emerging Medical Opportunities Fund II LP | 2014-03-31 | 32.8 M | |
| PE | New Emerging Medical Opportunities Fund LP | 2012-03-30 | 4.0 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 0.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 0.3 |
| By Discretionary | ||
| Discretionary | 8 | 0.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 0.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.3 | |
| United States Persons | 0.0 | |
| Total | 8 | 0.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Partners Ltd Sectoral Asset Management | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001274413] | |
| SC 13G | [0001274413] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $3.3B |
| Serves | Institutional, Retail |
| Fund Types | Private Equity |
| LEI | 254900KAKORD58ODPG76 |
| Comparable Firms | State | AUM |
|---|---|---|
|
LYNK Capital Management Company LLC
✚
|
FL | 359.6 M |
|
Twin Point Capital LLC
✚
|
NY | 355.9 M |
|
Cottonwood Ventures LLC
✚
|
TX | 347.3 M |
|
Millennial Advisers LLC
✚
|
NY | 339.4 M |
|
OCM Private Wealth LLC
✚
|
IL | 338.1 M |
|
Weik Capital Management Inc
✚
|
PA | 334.7 M |
|
Boston Family Advisors LLC
✚
|
MA | 329.7 M |
|
M4A3 LLC
✚
|
CO | 322.0 M |
|
Impact Investors Inc
✚
|
318.2 M | |
|
Adalta Capital Management LLC
✚
|
NY | 305.5 M |